| scholarly article | Q13442814 |
| P50 | author | Carlo Maria Croce | Q640381 |
| Matteo Fassan | Q39364695 | ||
| Vincenzo Coppola | Q40648671 | ||
| P2093 | author name string | Alessandro Laganà | |
| Giulia Romano | |||
| Paolo Fadda | |||
| Nicola Zanesi | |||
| Lara Rizzotto | |||
| Mario Acunzo | |||
| Raleigh Kladney | |||
| Luigi Fattore | |||
| Dario Veneziano | |||
| Giovanni Nigita | |||
| P2860 | cites work | Principles of microRNA-target recognition | Q21146368 |
| The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation | Q21562295 | ||
| KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 | ||
| Human MicroRNA targets | Q21563637 | ||
| Somatic activation of the K-ras oncogene causes early onset lung cancer in mice | Q40809826 | ||
| Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity | Q41626666 | ||
| Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints | Q42121608 | ||
| Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. | Q42564735 | ||
| The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. | Q54535188 | ||
| RAS oncogenes: the first 30 years. | Q55036584 | ||
| Cancer genome landscapes | Q22242276 | ||
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| MicroRNA targeting specificity in mammals: determinants beyond seed pairing | Q24607724 | ||
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| Detecting microRNA binding and siRNA off-target effects from expression data | Q24658272 | ||
| siRNA Versus miRNA as Therapeutics for Gene Silencing | Q26786876 | ||
| KRAS as a Therapeutic Target | Q27007866 | ||
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Causes and consequences of microRNA dysregulation in cancer | Q28258994 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics | Q28469345 | ||
| Specificity of microRNA target selection in translational repression | Q28776123 | ||
| The role of site accessibility in microRNA target recognition | Q29547436 | ||
| A comprehensive survey of Ras mutations in cancer | Q30416821 | ||
| miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs | Q33635585 | ||
| Development of siRNA payloads to target KRAS-mutant cancer | Q34287993 | ||
| 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets | Q34496075 | ||
| Drugging the undruggable RAS: Mission possible? | Q35163434 | ||
| Oncogenic Ras and its role in tumor cell invasion and metastasis | Q35690261 | ||
| Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding | Q36833119 | ||
| The genetics and biology of KRAS in lung cancer | Q37354111 | ||
| Isoform-specific ras functions in development and cancer | Q37401355 | ||
| Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy | Q38037048 | ||
| MicroRNA and cancer--a brief overview | Q38258057 | ||
| Targeting RAS-ERK signalling in cancer: promises and challenges | Q38272894 | ||
| K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. | Q38584436 | ||
| Therapeutic strategies for targeting ras proteins | Q39262217 | ||
| EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers | Q39430432 | ||
| Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. | Q40400258 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| limma | Q112236343 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| P304 | page(s) | E4203-E4212 | |
| P577 | publication date | 2017-05-08 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Selective targeting of point-mutated KRAS through artificial microRNAs | |
| P478 | volume | 114 |
| Q58584644 | A Simplified System to Express Circularized Inhibitors of miRNA for Stable and Potent Suppression of miRNA Functions |
| Q90634280 | A robust model for quantitative prediction of the silencing efficacy of wild-type and A-to-I edited miRNAs |
| Q92519642 | CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions |
| Q64059776 | Deregulation of a Network of mRNA and miRNA Genes Reveals That CK2 and MEK Inhibitors May Synergize to Induce Apoptosis KRAS-Active NSCLC |
| Q92712027 | Endogenous and artificial miRNAs explore a rich variety of conformations: a potential relationship between secondary structure and biological functionality |
| Q92155695 | Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression |
| Q49335684 | MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention. |
| Q91644121 | Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now? |
| Q91044879 | Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma |
| Q92050480 | The Butterfly Effect of RNA Alterations on Transcriptomic Equilibrium |
| Q88911796 | miRNAs reshape immunity and inflammatory responses in bacterial infection |
Search more.